IL324897A - Trem2 agonists - Google Patents
Trem2 agonistsInfo
- Publication number
- IL324897A IL324897A IL324897A IL32489725A IL324897A IL 324897 A IL324897 A IL 324897A IL 324897 A IL324897 A IL 324897A IL 32489725 A IL32489725 A IL 32489725A IL 324897 A IL324897 A IL 324897A
- Authority
- IL
- Israel
- Prior art keywords
- dimethyl
- chloro
- phenyl
- tetrahydropyran
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23179957 | 2023-06-19 | ||
| EP23211237 | 2023-11-21 | ||
| PCT/EP2024/066833 WO2024260929A1 (en) | 2023-06-19 | 2024-06-17 | Trem2 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL324897A true IL324897A (en) | 2026-01-01 |
Family
ID=91621082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL324897A IL324897A (en) | 2023-06-19 | 2024-06-17 | Trem2 agonists |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP4727934A1 (es) |
| JP (1) | JP2026521750A (es) |
| KR (1) | KR20260023587A (es) |
| CN (1) | CN121335893A (es) |
| AR (1) | AR132992A1 (es) |
| AU (1) | AU2024312352A1 (es) |
| CL (1) | CL2025004002A1 (es) |
| CO (1) | CO2025018165A2 (es) |
| CR (1) | CR20250537A (es) |
| IL (1) | IL324897A (es) |
| MX (1) | MX2025015264A (es) |
| PE (1) | PE20260310A1 (es) |
| TW (1) | TW202515878A (es) |
| WO (1) | WO2024260929A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2025206254A1 (en) | 2024-01-04 | 2026-06-11 | Muna Therapeutics Aps | Trem2 modulators |
| IL328677A (en) | 2024-01-04 | 2026-07-01 | Muna Therapeutics Aps | 2-Azatidinyl-7-methyl-8-oxo-6-(trifluoromethyl)-8,7-dihydropyrimido[4,5-D]pyrimidine derivatives as TREM2 modulators for the treatment of neurodegenerative diseases |
| WO2026077861A1 (en) * | 2024-10-07 | 2026-04-16 | F. Hoffmann-La Roche Ag | Trem2 agonists |
| WO2026115009A1 (en) * | 2024-11-29 | 2026-06-04 | F. Hoffmann-La Roche Ag | Trem2 agonists |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8318732B2 (en) * | 2008-07-02 | 2012-11-27 | Avexa Limited | Compounds having antiviral properties |
| EP4430029A4 (en) * | 2021-11-09 | 2025-09-10 | Vigil Neuroscience Inc | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL AGONISTS 2 AND METHODS OF USE |
-
2024
- 2024-06-17 PE PE2025003141A patent/PE20260310A1/es unknown
- 2024-06-17 KR KR1020267001588A patent/KR20260023587A/ko active Pending
- 2024-06-17 JP JP2025574086A patent/JP2026521750A/ja active Pending
- 2024-06-17 IL IL324897A patent/IL324897A/en unknown
- 2024-06-17 CN CN202480040255.2A patent/CN121335893A/zh active Pending
- 2024-06-17 EP EP24735173.7A patent/EP4727934A1/en active Pending
- 2024-06-17 WO PCT/EP2024/066833 patent/WO2024260929A1/en not_active Ceased
- 2024-06-17 CR CR20250537A patent/CR20250537A/es unknown
- 2024-06-17 AU AU2024312352A patent/AU2024312352A1/en active Pending
- 2024-06-18 AR ARP240101553A patent/AR132992A1/es unknown
- 2024-06-18 TW TW113122490A patent/TW202515878A/zh unknown
-
2025
- 2025-12-16 MX MX2025015264A patent/MX2025015264A/es unknown
- 2025-12-18 CL CL2025004002A patent/CL2025004002A1/es unknown
- 2025-12-18 CO CONC2025/0018165A patent/CO2025018165A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2025004002A1 (es) | 2026-04-06 |
| WO2024260929A1 (en) | 2024-12-26 |
| CO2025018165A2 (es) | 2026-01-23 |
| EP4727934A1 (en) | 2026-04-22 |
| MX2025015264A (es) | 2026-02-03 |
| TW202515878A (zh) | 2025-04-16 |
| JP2026521750A (ja) | 2026-07-01 |
| AU2024312352A1 (en) | 2025-12-11 |
| PE20260310A1 (es) | 2026-02-11 |
| AR132992A1 (es) | 2025-08-13 |
| CN121335893A (zh) | 2026-01-13 |
| CR20250537A (es) | 2026-01-19 |
| KR20260023587A (ko) | 2026-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11472794B2 (en) | Fused imidazole derivatives as IL-17 modulators | |
| CA3182105A1 (en) | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | |
| WO2024260929A1 (en) | Trem2 agonists | |
| JP2024519496A (ja) | ブルトンのチロシンキナーゼの分解を標的化するための化合物 | |
| TW202309029A (zh) | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 | |
| JP7669299B2 (ja) | 複素環モノアシルグリセロールリパーゼ(magl)阻害剤 | |
| CA3215260A1 (en) | Heterocyclic compounds | |
| JP2019089828A (ja) | オータキシン阻害剤としての新規オクタヒドロ−ピロロ[3,4−c]−ピロール誘導体及びそのアナログ | |
| CA2947338A1 (en) | Multi-fluoro-substituted compound as bruton's tyrosine kinase (btk) inhibitor | |
| JP2025540958A (ja) | 蕁麻疹の治療のための野生型c-kitキナーゼ阻害剤としてのN-フェニル-ピラゾロ[1,5-A]ピリジン-3-カルボキサミド誘導体 | |
| JP2023510874A (ja) | 置換ピラゾロ-ピリミジンおよびその使用 | |
| WO2024246018A1 (en) | Trem2 agonists | |
| WO2024246019A1 (en) | Pyrido[3,4-d]pyrimidin-4-one and pyrimido[5,4-d]pyrimidin-4-one derivatives as trem2 agonists for the treatment of parkinson's disease | |
| WO2025176748A1 (en) | Condensed pyrazines or pyrimidines als trem2 agoonists | |
| WO2023239846A1 (en) | Heterocyclic compounds as pi3kα inhibitors | |
| JP2025503438A (ja) | モノアシルグリセロールリパーゼ阻害剤として有用な二環式複素環化合物 | |
| WO2026077862A1 (en) | Trem2 agonists | |
| WO2026077861A1 (en) | Trem2 agonists | |
| WO2025176753A1 (en) | Condensed pyrimidine derivates als trem2 agonists | |
| HK40129411A (en) | Pyrido[3,4-d]pyrimidin-4-one and pyrimido[5,4-d]pyrimidin-4-one derivatives as trem2 agonists for the treatment of parkinson's disease | |
| WO2026087634A1 (en) | Trem2 agonists | |
| TW202615031A (zh) | 作為可溶性環氧化物水解酶抑制劑之吡啶酮甲醯胺衍生型化合物 | |
| WO2025125135A1 (en) | Spiropiperidine urea-derived compounds as soluble epoxide hydrolase inhibitors | |
| EA051229B1 (ru) | Гетероциклические соединения |